| Lauren E Monroe, ANP | |
|
266 Joule St, Alcoa, TN 37701-2422 | |
| (865) 984-3864 | |
| (865) 380-4095 |
| Full Name | Lauren E Monroe |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 15 Years |
| Location | 266 Joule St, Alcoa, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134452378 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2200X | Nurse Practitioner - Adult Health | APN14185 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Tn Medical Center | Knoxville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Health System, Inc. | 5294646378 | 526 |
News Archive
To get a better look at the abnormalities that cause age-related macular degeneration (AMD), the leading cause of vision loss in Americans and Europeans over 50, the research groups of James Fujimoto at the Massachusetts Institute of Technology (MIT) and collaborators Jay Duker of the Tufts University School of Medicine, and Joel Schuman of the University of Pittsburgh School of Medicine have created ultra-detailed 3-D images of the eyes of more than 2,000 people from different ethnic groups, 400 of whom have AMD.
Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has granted Jose M. Garcia, MD, PhD, Assistant Professor, Division of Diabetes Endocrinology and Metabolism, Departments of Medicine and Molecular and Cell Biology, Baylor College of Medicine and Michael I. DeBakey Veterans Administration Medical Center, in Houston Texas, an Investigational New Drug approval for the initiation of a Phase 2A trial to assess the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130, in patients with cancer cachexia.
More U.S. adults reported receiving or planning to receive an influenza vaccination during the 2020-2021 flu season than ever before, according to findings from a December 2020 national survey.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
InterMune, Inc. announced today that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®.
› Verified 1 days ago
| Entity Name | University Health System, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790738763 PECOS PAC ID: 5294646378 Enrollment ID: O20031111000809 |
News Archive
To get a better look at the abnormalities that cause age-related macular degeneration (AMD), the leading cause of vision loss in Americans and Europeans over 50, the research groups of James Fujimoto at the Massachusetts Institute of Technology (MIT) and collaborators Jay Duker of the Tufts University School of Medicine, and Joel Schuman of the University of Pittsburgh School of Medicine have created ultra-detailed 3-D images of the eyes of more than 2,000 people from different ethnic groups, 400 of whom have AMD.
Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has granted Jose M. Garcia, MD, PhD, Assistant Professor, Division of Diabetes Endocrinology and Metabolism, Departments of Medicine and Molecular and Cell Biology, Baylor College of Medicine and Michael I. DeBakey Veterans Administration Medical Center, in Houston Texas, an Investigational New Drug approval for the initiation of a Phase 2A trial to assess the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130, in patients with cancer cachexia.
More U.S. adults reported receiving or planning to receive an influenza vaccination during the 2020-2021 flu season than ever before, according to findings from a December 2020 national survey.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
InterMune, Inc. announced today that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®.
› Verified 1 days ago
| Entity Name | Uhs Cardiology Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083039820 PECOS PAC ID: 9830322171 Enrollment ID: O20140512001403 |
News Archive
To get a better look at the abnormalities that cause age-related macular degeneration (AMD), the leading cause of vision loss in Americans and Europeans over 50, the research groups of James Fujimoto at the Massachusetts Institute of Technology (MIT) and collaborators Jay Duker of the Tufts University School of Medicine, and Joel Schuman of the University of Pittsburgh School of Medicine have created ultra-detailed 3-D images of the eyes of more than 2,000 people from different ethnic groups, 400 of whom have AMD.
Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has granted Jose M. Garcia, MD, PhD, Assistant Professor, Division of Diabetes Endocrinology and Metabolism, Departments of Medicine and Molecular and Cell Biology, Baylor College of Medicine and Michael I. DeBakey Veterans Administration Medical Center, in Houston Texas, an Investigational New Drug approval for the initiation of a Phase 2A trial to assess the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130, in patients with cancer cachexia.
More U.S. adults reported receiving or planning to receive an influenza vaccination during the 2020-2021 flu season than ever before, according to findings from a December 2020 national survey.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
InterMune, Inc. announced today that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lauren E Monroe, ANP Po Box 5358, Maryville, TN 37802-5358 Ph: (865) 984-3864 | Lauren E Monroe, ANP 266 Joule St, Alcoa, TN 37701-2422 Ph: (865) 984-3864 |
News Archive
To get a better look at the abnormalities that cause age-related macular degeneration (AMD), the leading cause of vision loss in Americans and Europeans over 50, the research groups of James Fujimoto at the Massachusetts Institute of Technology (MIT) and collaborators Jay Duker of the Tufts University School of Medicine, and Joel Schuman of the University of Pittsburgh School of Medicine have created ultra-detailed 3-D images of the eyes of more than 2,000 people from different ethnic groups, 400 of whom have AMD.
Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has granted Jose M. Garcia, MD, PhD, Assistant Professor, Division of Diabetes Endocrinology and Metabolism, Departments of Medicine and Molecular and Cell Biology, Baylor College of Medicine and Michael I. DeBakey Veterans Administration Medical Center, in Houston Texas, an Investigational New Drug approval for the initiation of a Phase 2A trial to assess the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130, in patients with cancer cachexia.
More U.S. adults reported receiving or planning to receive an influenza vaccination during the 2020-2021 flu season than ever before, according to findings from a December 2020 national survey.
Peplin, Inc. (ASX:PLI) today announced completion of enrolment in its second Phase 3 clinical trial for the use of PEP005 (ingenol mebutate) Gel to treat actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, on non-head treatment areas, which include the trunk and extremities. This completes enrolment in the final of four pivotal trials planned for the submission of the New Drug Application (NDA) for AK.
InterMune, Inc. announced today that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®.
› Verified 1 days ago
Melanie Bankerd, F.N.P. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 266 Joule St, Alcoa, TN 37701 Phone: 865-984-3864 Fax: 865-380-4095 | |
Katherine Elizabeth Whittington, MSN, PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 255 E Watt St, Alcoa, TN 37701 Phone: 865-273-1616 Fax: 865-273-1645 | |
Michael E Lowe, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 212 Heighton Ct, Alcoa, TN 37701 Phone: 865-556-2672 | |
Caytlin Grae Cardwell, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 255 E Watt St, Alcoa, TN 37701 Phone: 865-273-1616 Fax: 865-273-1645 | |
Mrs. Lori M. Ervin, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 266 Joule St, Alcoa, TN 37701 Phone: 865-984-3864 | |
Summer Dobbs Brooks, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 266 Joule St, Alcoa, TN 37701 Phone: 865-984-3864 Fax: 865-380-4095 |